The leading drug developers already work with Tempus.

AstraZeneca

+5 percentage points in Probability of Technical Success across the Oncology R&D portfolio.

Tempus embedded across AstraZeneca’s clinical trial design governance. A joint steering committee with 20 dedicated FTEs scaled a 1–5 trial pilot to 10–40 trials per year.

Mirati Therapeutics

Real-world data contextualized Phase 2 results, supporting FDA accelerated approval of adagrasib.

A propensity-matched cohort drawn from de-identified US oncology data contextualized KRYSTAL-1 against standard of care, and refined patient selection for the confirmatory Phase 3 in 1L NSCLC.

Pfizer

HER2-targetable populations identified across new solid tumor indications.

Whole-transcriptome RNA analysis of 4,000+ multimodal patient records uncovered HER2 expression patterns in head & neck, lung, endometrial, and ovarian cancers. Findings presented at AACR 2024.

Validating a novel target and informing trial design for a first-in-class therapeutic

Tempus’s de-identified multimodal data supported validation of a novel target and informed trial design for a first-in-class therapeutic.

Real-world external controls for regulatory decision-making

A biotech needed to contextualize its Phase 1b/2a trial for mNSCLC patients with a specific mutation. Tempus constructed a real-world external control arm as a benchmark for the regulatory submission.

Guiding indication expansion with multimodal real-world data

Analysis of biomarker prevalence across Tempus’s multimodal real-world data helped identify new opportunities, prioritize R&D, and inform future trial design.

Reduce time to launch with Tempus and multimodal data

A biopharma simplified its development approach to TROPION-Lung01, driving down time to launch and saving the cost of an unnecessary Phase III study.

Uncovering spatial biomarkers in NSCLC to refine immuno-oncology clinical trial strategy

Learn how Tempus’ multimodal platform, combining spatial transcriptomics with genomic and clinical data, helped a biopharma partner identify novel spatial biomarkers to create an actionable patient stratification strategy for an immuno-oncology clinical trial.

Biomarker-driven strategy for a first-in-class inhibitor in bladder cancer

A biomarker signal in bladder cancer patients treated with anti-PD-L1 therapies — amplification of the target gene was associated with worse outcomes. The findings shaped the biotech’s view of an underserved patient population.